Sign inCreate account

Report workspace tools

NCT04842682COMPLETEDanonymous

A Phase I Multicenter Double-blind Placebo Controlled Dose Escalation Trial of an Adjuvanted Anti-CD40 mAb Fused to Env GP140 HIV Clade C ZM-96 (CD40.HIVRI.Env) Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Participants

Sponsor

Source record

ANRS, Emerging Infectious Diseases

Phase

Source record

Phase I

Modality

AI-normalized

protein therapy

Target

AI-normalized

HIV-1 Vaccine

Indication / condition

AI-normalized

Healthy Adults

Intervention

Source record

Solo 0.3 group, Solo 1 group, Solo 3 group, Combi 0.3 group, Combi 1 group, Combi 3 group, Late boost CD40 alone, Late boost CD40 adjuvanted

Source & freshness

Source record

NCT ID

NCT04842682

Original source

ClinicalTrials.gov

Source last updated

Dec 17, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04842682

Title

A Phase I Multicenter Double-blind Placebo Controlled Dose Escalation Trial of an Adjuvanted Anti-CD40 mAb Fused to Env GP140 HIV Clade C ZM-96 (CD40.HIVRI.Env) Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Participants

Sponsor

ANRS, Emerging Infectious Diseases

Status

COMPLETED

Phase

Phase I

Condition raw

Healthy Adults

Condition normalized

Healthy Adults

Modality raw

Healthy Adults

Modality normalized

protein therapy

Target raw

HIV-1 Vaccine

Target normalized

HIV-1 Vaccine

Interventions

Solo 0.3 group, Solo 1 group, Solo 3 group, Combi 0.3 group, Combi 1 group, Combi 3 group, Late boost CD40 alone, Late boost CD40 adjuvanted

Public preview

Source record

The trial evaluates the safety and immunogenicity of the CD40.HIVRI.Env vaccine, both alone and in combination with the DNA-HIV-PT123 vaccine, in healthy volunteers. Conducted in France and Switzerland, it aims to establish a dose escalation strategy with a total enrollment of 72 participants. The study is sponsored by ANRS, Emerging Infectious Diseases.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I Multicenter Double-blind Placebo Controlled Dose Escalation Trial of an Adjuvanted Anti-CD40 mAb Fused to Env GP140 HIV Clade C ZM-96 (CD40.HIVRI.Env) Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Participants

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04842682

Status

COMPLETED

Phase

Phase I

Sponsor

ANRS, Emerging Infectious Diseases

Executive brief

Investment-Ready Snapshot

The trial evaluates the safety and immunogenicity of the CD40.HIVRI.Env vaccine, both alone and in combination with the DNA-HIV-PT123 vaccine, in healthy volunteers. Conducted in France and Switzerland, it aims to establish a dose escalation strategy with a total enrollment of 72 participants. The study is sponsored by ANRS, Emerging Infectious Diseases.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 17, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04842682

Indication

Healthy Adults

Modality

protein therapy

Target

HIV-1 Vaccine

Intervention

Solo 0.3 group, Solo 1 group, Solo 3 group, Combi 0.3 group, Combi 1 group, Combi 3 group, Late boost CD40 alone, Late boost CD40 adjuvanted

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.